近期病原体表明需要改进的情境意识能力，例如 Co-Dx PCR 现场检测平台所提供的能力
紧随埃博拉疫情爆发和世界卫生组织紧急声明，以及增强的疾病控制与预防中心旅行者筛查措施
, /PRNewswire/ -- Co-Diagnostics, Inc.（纳斯达克：CODX）（&#34;Co-Dx&#34; 或 &#34;公司&#34;），是一家拥有独特专利平台的分子诊断公司，专注于分子诊断测试的开发，今天宣布已完成针对目前在刚果民主共和国和乌干达引发埃博拉疫情的 Bundibugyo 病毒（&#34;BDBV&#34;）的检测开发策略。
&#34;我们很高兴地报告，我们已完成 BDBV 的检测开发策略，如果出现需要该检测的情况，我们预计能够迅速执行该策略并使测试可用，&#34; Co-Diagnostics 首席执行官 Dwight Egan 说。&#34;除了快速、黄金标准 PCR 诊断在识别感染患者和帮助限制埃博拉等致命疾病传播方面的作用外，我们认为近期事件还强调了去中心化诊断和实时情境意识在帮助公共卫生当局追踪和控制疫情中的日益重要性。&#34;
5 月 17 日，世界卫生组织宣布由 BDBV 引起的埃博拉疫情为国际关注的公共卫生紧急事件（&#34;PHEIC&#34;）。截至 5 月 17 日，刚果民主共和国报告了 8 例实验室确诊病例、246 例疑似病例和 80 例疑似死亡病例，乌干达则报告了 2 例实验室确诊病例和 1 例死亡病例。
该公告还跟随美国疾病控制与预防中心（&#34;CDC&#34;）关于增强来自埃博拉疫情影响地区的旅行者筛查和监测措施的最新指导。根据 CDC 的说法，这些措施包括增加旅行者监测、接触追踪协调和增强医院准备工作，强调了快速检测和实时疫情可见性在应对新兴传染病威胁中的重要性。
Egan 先生补充道，&#34;COVID-19 大流行强化了对新兴传染病威胁的准备和快速响应能力的重要性，我们认为在这些情况出现时迅速响应是非常重要的。我们设计 Co-Dx PCR 平台 * 时考虑了这些需求，包括支持去中心化检测和云连接架构的能力。实时了解疫情活动可以在帮助公共卫生当局识别、监测和应对新兴传染病威胁方面发挥重要作用。我们期待与政府和非政府机构及组织在未来开发该检测方面的合作，视需要而定。&#34;
*Co-Dx PCR 平台（包括 PCR Home®、PCR Pro®、移动应用程序及所有相关测试）正在接受 FDA 和/或其他监管机构的审查，目前尚未上市销售。
关于 Co-Diagnostics, Inc.: Co-Diagnostics, Inc. 是一家位于犹他州的分子诊断公司，开发、制造和销售先进的诊断技术。公司的技术用于设计基于核酸分子（DNA 或 RNA）检测和/或分析的测试。公司还利用其专有技术为其 Co-Dx PCR 家庭和现场检测平台（正在接受监管审查，尚未上市销售）设计特定测试，并识别用于其他应用的遗传标记。
前瞻性声明： 本新闻稿包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明可以通过诸如 “相信”、“期望”、“估计”、“打算”、“可能”、“计划”、“将”、“寻求”、“预期” 等词语或这些词的否定形式来识别。本新闻稿中的前瞻性声明包括但不限于以下内容：(i) 公司执行其 Bundibugyo 病毒（“BDBV”）检测开发战略的能力；(ii) BDBV 检测的潜在未来开发、验证、监管审查、商业化、生产和分发；(iii) 公司快速应对新兴传染病威胁的能力；(iv) Co-Dx PCR 平台在去中心化诊断和疫情监测中的潜在效用、有效性和采用；(v) 实时态势感知和云连接诊断系统在公共卫生应对工作中的潜在作用；(vi) 与政府和非政府组织在传染病准备和应对方面的潜在合作。这些声明面临许多风险和不确定性，包括但不限于：市场需求或公共卫生状况可能发生变化的风险；与公司成功开发、验证、获得监管授权或批准、生产和商业化任何 BDBV 检测或相关产品的能力相关的风险；与 FDA 或其他监管机构的监管审查相关的风险；与 Co-Dx PCR 平台的性能、可靠性和市场接受度相关的风险；与对第三方、供应商、合作伙伴和分销商的依赖相关的风险；与竞争、技术变革和知识产权保护相关的风险； 以及公司不时在向证券交易委员会（“SEC”）提交的文件中描述的其他风险。实际结果可能与这些前瞻性声明中表达或暗示的结果有实质性差异。提醒读者不要对前瞻性声明过度依赖。有关风险和不确定性的进一步描述可以在公司于 2026 年 3 月 31 日向证券交易委员会提交的 10-K 表格年度报告及其其他 SEC 文件中找到。除非适用法律要求，公司没有义务更新任何前瞻性声明，以反映本新闻稿日期后的事件或情况。
来源 Co-Diagnostics
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MjcwNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkwOTAwUFJfTkVXU19VU1BSX19fX19MQTYyNzA3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MjcwNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkwOTAwUFJfTkVXU19VU1BSX19fX19MQTYyNzA3"/>

CODX

Co-Diagnostics, Inc. 在刚果民主共和国和乌干达最近的埃博拉疫情后，开发了一种针对 Bundibugyo 病毒（BDBV）的检测策略。该公司强调快速 PCR 诊断和实时情况意识在应对传染病威胁中的重要性。随着世界卫生组织宣布此次疫情为公共卫生紧急事件，Co-Diagnostics 旨在与卫生当局合作，以确保应对准备和快速反应能力

Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform
<div class="lb-trans">近期病原体表明需要改进的情境意识能力，例如 Co-Dx PCR 现场检测平台所提供的能力
</div>Follows outbreak of Ebola and WHO emergency declaration, and enhanced CDC traveler screening measures
<div class="lb-trans">紧随埃博拉疫情爆发和世界卫生组织紧急声明，以及增强的疾病控制与预防中心旅行者筛查措施
</div>, /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (&#34;Co-Dx&#34; or &#34;the Company&#34;), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has completed the assay development strategy for the Bundibugyo virus (&#34;BDBV&#34;) currently causing an outbreak of Ebola disease in the Democratic Republic of the Congo and Uganda.
<div class="lb-trans">, /PRNewswire/ -- Co-Diagnostics, Inc.（纳斯达克：CODX）（&#34;Co-Dx&#34; 或 &#34;公司&#34;），是一家拥有独特专利平台的分子诊断公司，专注于分子诊断测试的开发，今天宣布已完成针对目前在刚果民主共和国和乌干达引发埃博拉疫情的 Bundibugyo 病毒（&#34;BDBV&#34;）的检测开发策略。
</div>&#34;We are pleased to report that we have completed the assay development strategy for BDBV, and should a situation arise requiring the assay, we expect we would be well positioned to execute the strategy and rapidly make the test available,&#34; said Dwight Egan, Co-Diagnostics Chief Executive Officer. &#34;In addition to the role that rapid, gold-standard PCR diagnostics can play in identifying infected patients and helping limit the spread of deadly diseases like Ebola, we believe recent events also underscore the growing importance of decentralized diagnostics and real-time situational awareness in helping public health authorities track and contain outbreaks.&#34;
<div class="lb-trans">&#34;我们很高兴地报告，我们已完成 BDBV 的检测开发策略，如果出现需要该检测的情况，我们预计能够迅速执行该策略并使测试可用，&#34; Co-Diagnostics 首席执行官 Dwight Egan 说。&#34;除了快速、黄金标准 PCR 诊断在识别感染患者和帮助限制埃博拉等致命疾病传播方面的作用外，我们认为近期事件还强调了去中心化诊断和实时情境意识在帮助公共卫生当局追踪和控制疫情中的日益重要性。&#34;
</div>On May 17, WHO declared an outbreak of Ebola disease caused by BDBV as a public health emergency of international concern (&#34;PHEIC&#34;). As of May 17, eight laboratory-confirmed cases, 246 suspected cases, and 80 suspected deaths have been reported in the Democratic Republic of the Congo, along with two laboratory-confirmed cases and one reported death in Uganda.
<div class="lb-trans">5 月 17 日，世界卫生组织宣布由 BDBV 引起的埃博拉疫情为国际关注的公共卫生紧急事件（&#34;PHEIC&#34;）。截至 5 月 17 日，刚果民主共和国报告了 8 例实验室确诊病例、246 例疑似病例和 80 例疑似死亡病例，乌干达则报告了 2 例实验室确诊病例和 1 例死亡病例。
</div>The announcement also follows recent guidance from the U.S. Centers for Disease Control and Prevention (&#34;CDC&#34;) regarding enhanced screening and monitoring measures for travelers arriving from regions impacted by Ebola outbreaks. According to the CDC, these measures include increased traveler monitoring, contact tracing coordination, and enhanced hospital preparedness efforts, underscoring the importance of rapid testing and real-time outbreak visibility in responding to emerging infectious disease threats.
<div class="lb-trans">该公告还跟随美国疾病控制与预防中心（&#34;CDC&#34;）关于增强来自埃博拉疫情影响地区的旅行者筛查和监测措施的最新指导。根据 CDC 的说法，这些措施包括增加旅行者监测、接触追踪协调和增强医院准备工作，强调了快速检测和实时疫情可见性在应对新兴传染病威胁中的重要性。
</div>Mr. Egan added, &#34;The COVID-19 pandemic reinforced the importance of preparedness and rapid response capabilities for emerging infectious disease threats, and we believe it is important to be positioned to respond quickly as we have in the past when situations like these have emerged. We designed the Co-Dx PCR platform* with these types of needs in mind, including the ability to support decentralized testing and cloud-connected architecture. Real-time visibility into outbreak activity can play an important role in helping public health authorities identify, monitor, and respond to emerging infectious disease threats. We look forward to collaboration with governmental and non-governmental agencies and organizations on the future development of this test, as needed.&#34;
<div class="lb-trans">Egan 先生补充道，&#34;COVID-19 大流行强化了对新兴传染病威胁的准备和快速响应能力的重要性，我们认为在这些情况出现时迅速响应是非常重要的。我们设计 Co-Dx PCR 平台 * 时考虑了这些需求，包括支持去中心化检测和云连接架构的能力。实时了解疫情活动可以在帮助公共卫生当局识别、监测和应对新兴传染病威胁方面发挥重要作用。我们期待与政府和非政府机构及组织在未来开发该检测方面的合作，视需要而定。&#34;
</div>*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
<div class="lb-trans">*Co-Dx PCR 平台（包括 PCR Home®、PCR Pro®、移动应用程序及所有相关测试）正在接受 FDA 和/或其他监管机构的审查，目前尚未上市销售。
</div>About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
<div class="lb-trans">关于 Co-Diagnostics, Inc.: Co-Diagnostics, Inc. 是一家位于犹他州的分子诊断公司，开发、制造和销售先进的诊断技术。公司的技术用于设计基于核酸分子（DNA 或 RNA）检测和/或分析的测试。公司还利用其专有技术为其 Co-Dx PCR 家庭和现场检测平台（正在接受监管审查，尚未上市销售）设计特定测试，并识别用于其他应用的遗传标记。
</div>Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as &#34;believes,&#34; &#34;expects,&#34; &#34;estimates,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;plans,&#34; &#34;will,&#34; &#34;seeks,&#34; &#34;anticipates,&#34; and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding: (i) the Company's ability to execute its assay development strategy for Bundibugyo virus (&#34;BDBV&#34;); (ii) the potential future development, validation, regulatory review, commercialization, manufacture, and distribution of a BDBV test; (iii) the Company's ability to rapidly respond to emerging infectious disease threats; (iv) the potential utility, effectiveness, and adoption of the Co-Dx PCR platform for decentralized diagnostics and outbreak monitoring; (v) the potential role of real-time situational awareness and cloud-connected diagnostic systems in public health response efforts; and (vi) potential collaborations with governmental and non-governmental organizations relating to infectious disease preparedness and response. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that market demand or public health conditions may change; risks related to the Company's ability to successfully develop, validate, obtain regulatory authorization or approval for, manufacture, and commercialize any BDBV assay or related products; risks related to regulatory review by the FDA or other regulatory authorities; risks related to the performance, reliability, and market acceptance of the Co-Dx PCR platform; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission (&#34;SEC&#34;). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
<div class="lb-trans">前瞻性声明： 本新闻稿包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明。前瞻性声明可以通过诸如 “相信”、“期望”、“估计”、“打算”、“可能”、“计划”、“将”、“寻求”、“预期” 等词语或这些词的否定形式来识别。本新闻稿中的前瞻性声明包括但不限于以下内容：(i) 公司执行其 Bundibugyo 病毒（“BDBV”）检测开发战略的能力；(ii) BDBV 检测的潜在未来开发、验证、监管审查、商业化、生产和分发；(iii) 公司快速应对新兴传染病威胁的能力；(iv) Co-Dx PCR 平台在去中心化诊断和疫情监测中的潜在效用、有效性和采用；(v) 实时态势感知和云连接诊断系统在公共卫生应对工作中的潜在作用；(vi) 与政府和非政府组织在传染病准备和应对方面的潜在合作。这些声明面临许多风险和不确定性，包括但不限于：市场需求或公共卫生状况可能发生变化的风险；与公司成功开发、验证、获得监管授权或批准、生产和商业化任何 BDBV 检测或相关产品的能力相关的风险；与 FDA 或其他监管机构的监管审查相关的风险；与 Co-Dx PCR 平台的性能、可靠性和市场接受度相关的风险；与对第三方、供应商、合作伙伴和分销商的依赖相关的风险；与竞争、技术变革和知识产权保护相关的风险； 以及公司不时在向证券交易委员会（“SEC”）提交的文件中描述的其他风险。实际结果可能与这些前瞻性声明中表达或暗示的结果有实质性差异。提醒读者不要对前瞻性声明过度依赖。有关风险和不确定性的进一步描述可以在公司于 2026 年 3 月 31 日向证券交易委员会提交的 10-K 表格年度报告及其其他 SEC 文件中找到。除非适用法律要求，公司没有义务更新任何前瞻性声明，以反映本新闻稿日期后的事件或情况。
</div>SOURCE Co-Diagnostics
<div class="lb-trans">来源 Co-Diagnostics
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9TEE2MjcwNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkwOTAwUFJfTkVXU19VU1BSX19fX19MQTYyNzA3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA62707&amp;Transmission_Id=202605190900PR_NEWS_USPR_____LA62707&amp;DateId=20260519"/>

09:00 ETCo-Diagnostics 在近期全球爆发警报后开发埃博拉检测策略